Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01874457|
Recruitment Status : Completed
First Posted : June 11, 2013
Last Update Posted : June 17, 2013
|Condition or disease||Intervention/treatment|
|Mumps Rubella Measles||Biological: MMR (Mumps, Measles and Rubella)|
|Study Type :||Observational|
|Actual Enrollment :||150 participants|
|Official Title:||A Serological Study of Measles, Mumps and Rubella in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella) in Health Centers Where a Phase III Study Should be Conducted|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||March 2009|
|Actual Study Completion Date :||August 2009|
Biological: MMR (Mumps, Measles and Rubella)
- Immunoresponse after first dose [ Time Frame: 42 days ]Assess the immunoresponse for measles, mumps and rubella after vaccination with MMR in children 12-23 months and 29 days old, in the routine of National Immunization Program (NIP) in health units in the city of Rio de Janeiro.
- Immunoresponse after revaccination [ Time Frame: 42 days ]To evaluate the immunoresponse after revaccination of children who did not seroconvert for any of the three components of the vaccine.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01874457
|Rio de Janeiro, Brazil, 21040-360|
|Principal Investigator:||Glória Regina da Silva e Sá, Doctorate||Immunobiological Technology Institute (Bio-Manguinhos)|